FRAMINGHAM, Mass. & BOSTON–(BUSINESS WIRE)–Variantyx (www.variantyx.com) today announced the integration of its clinical whole genome testing pipeline with FDNA’s (www.fdna.com) Face2Gene suite of applications. Using its proprietary Genomic Intelligence® platform, Variantyx provides end-to-end clinical diagnostic services for rare genetic disorders based on comprehensive whole genome sequencing (WGS). Integration with Face2Gene technology now enables clinicians worldwide to send information about the phenotypes, syndromes, and genes that correlate with a patient’s facial and clinical analysis to Variantyx directly, speeding analysis and improving variant interpretation.
The Evolution of FDNA’s technology: An Interview with Aviram Bar Haim
Analyzing facial features has long been a vital step in diagnosing genetic syndromes. In recent years, AI-driven technologies have transformed this process, making it more efficient and accurate. Leading this innovation is Face2Gene, an advanced AI platform that leverages machine learning to assist clinicians in identifying genetic disorders. To explore the development of this groundbreaking […]
